OBJECTIVES: The aim of this study was to confirm the generalizability of the conclusions of the STICH (Surgical Treatment for Ischemic Heart Failure) trial. BACKGROUND:Surgical ventricular reconstruction (SVR) added to coronary artery bypass grafting (CABG) did not decrease death or cardiac hospitalization in STICH patients randomized to CABG with (n = 501) or without (n = 499) SVR. METHODS: Baseline clinical characteristics of 1,000 STICH SVR hypothesis patients and 1,036 STICH-eligible Society of Thoracic Surgeons (STS) National Cardiac Database patients undergoing CABG plus SVR were entered into a multivariate model equation to predict a mortality that placed these 2,036 patients in 1 of 32 risk at randomization (RAR) groups. The number of patients in each RAR group profiled the risk of STICH treatment arms and of STICH and STS STICH-eligible patients. RESULTS: That 85% of the 1,000 STICH patients known to have no significant differences in baseline characteristics between the 2 treatment arms shared the same RAR group suggests that the RAR methodology has sufficient accuracy to compare RAR profiles of STICH and STS patients. RAR group was shared by 1,522 of 2,036 STICH and STS STICH-eligible patients (75%) who underwent CABG plus SVR. Differences in baseline characteristics responsible for more low-risk STICH patients and more high-risk STS patients were modest. Cox proportional hazard ratios of 1,000 STICH patients in 3 RAR groups suggested by STICH and STS RAR differences showed no differential treatment effect on survival across the low-, intermediate-, and high-risk groups. CONCLUSIONS: The STICH conclusion of no benefit from adding SVR to CABG applies to a broad spectrum of CABG-eligible patients with ischemic cardiomyopathy. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease; NCT00023595). Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
RCT Entities:
OBJECTIVES: The aim of this study was to confirm the generalizability of the conclusions of the STICH (Surgical Treatment for Ischemic Heart Failure) trial. BACKGROUND: Surgical ventricular reconstruction (SVR) added to coronary artery bypass grafting (CABG) did not decrease death or cardiac hospitalization in STICH patients randomized to CABG with (n = 501) or without (n = 499) SVR. METHODS: Baseline clinical characteristics of 1,000 STICH SVR hypothesis patients and 1,036 STICH-eligible Society of Thoracic Surgeons (STS) National Cardiac Database patients undergoing CABG plus SVR were entered into a multivariate model equation to predict a mortality that placed these 2,036 patients in 1 of 32 risk at randomization (RAR) groups. The number of patients in each RAR group profiled the risk of STICH treatment arms and of STICH and STS STICH-eligible patients. RESULTS: That 85% of the 1,000 STICH patients known to have no significant differences in baseline characteristics between the 2 treatment arms shared the same RAR group suggests that the RAR methodology has sufficient accuracy to compare RAR profiles of STICH and STS patients. RAR group was shared by 1,522 of 2,036 STICH and STS STICH-eligible patients (75%) who underwent CABG plus SVR. Differences in baseline characteristics responsible for more low-risk STICH patients and more high-risk STS patients were modest. Cox proportional hazard ratios of 1,000 STICH patients in 3 RAR groups suggested by STICH and STS RAR differences showed no differential treatment effect on survival across the low-, intermediate-, and high-risk groups. CONCLUSIONS: The STICH conclusion of no benefit from adding SVR to CABG applies to a broad spectrum of CABG-eligible patients with ischemic cardiomyopathy. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease; NCT00023595). Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Robert H Jones; Harvey White; Eric J Velazquez; Linda K Shaw; Ricardo Pietrobon; Julio A Panza; Robert O Bonow; George Sopko; Christopher M O'Connor; Jean-Lucien Rouleau Journal: J Am Coll Cardiol Date: 2010-08-03 Impact factor: 24.094
Authors: Adrian F Hernandez; Eric J Velazquez; Mercedes K C Dullum; Sean M O'Brien; T Bruce Ferguson; Eric D Peterson Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: Eric J Velazquez; Kerry L Lee; Christopher M O'Connor; Jae K Oh; Robert O Bonow; Gerald M Pohost; Arthur M Feldman; Daniel B Mark; Julio A Panza; George Sopko; Jean L Rouleau; Robert H Jones Journal: J Thorac Cardiovasc Surg Date: 2007-12 Impact factor: 5.209
Authors: Lorenzo Menicanti; Serenella Castelvecchio; Marco Ranucci; Alessandro Frigiola; Carlo Santambrogio; Carlo de Vincentiis; Jelena Brankovic; Marisa Di Donato Journal: J Thorac Cardiovasc Surg Date: 2007-06-18 Impact factor: 5.209
Authors: David L Prior; Susanna R Stevens; Thomas A Holly; Michal Krejca; Alexandros Paraforos; Gerald M Pohost; Krysti Byrd; Tomasz Kukulski; Robert H Jones; Patrice Desvigne-Nickens; Padmini Varadarajan; Aman Amanullah; Grace Lin; Hussein R Al-Khalidi; Gabriel Aldea; Carlo Santambrogio; Andrzej Bochenek; Daniel S Berman Journal: Heart Date: 2017-04-26 Impact factor: 5.994
Authors: Tomasz Kukulski; Lilin She; Normand Racine; Sinisa Gradinac; Julio A Panza; Eric J Velazquez; Kwan Chan; Mark C Petrie; Kerry L Lee; Patricia A Pellikka; Alexander Romanov; Jolanta Biernat; Jean L Rouleau; Carmen Batlle; Jan Rogowski; Paolo Ferrazzi; Marian Zembala; Jae K Oh Journal: J Thorac Cardiovasc Surg Date: 2014-10-05 Impact factor: 5.209
Authors: Kyung-Hee Kim; Lilin She; Kerry L Lee; Rafal Dabrowski; Paul A Grayburn; Miroslaw Rajda; David L Prior; Patrice Desvigne-Nickens; William A Zoghbi; Michele Senni; Guglielmo Stefanelli; Cesare Beghi; Thao Huynh; Eric J Velazquez; Jae K Oh; Grace Lin Journal: Cardiovasc Ultrasound Date: 2020-05-28 Impact factor: 2.062